It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
KANK1 is expressed in epithelial cells and connects focal adhesions with the adjacent cortical microtubule stabilizing complex. Although KANK1 was shown to suppress cancer cell growth in vitro, TCGA database points to high KANK1 levels associated with poor prognosis in a wide spectrum of human malignancies. Here, we address this discrepancy and report that KANK1 promotes proliferation and survival of PyMT-transformed mammary tumor cells in vivo. Mechanistically, KANK1 localizes to the basal side of basement membrane (BM)-attached transformed luminal epithelial cells. When these cells lose the contact with the BM and disassemble integrin adhesions, KANK1 is found at cell-cell junctions where it competes with the polarity and tumor suppressor Scribble for NOS1AP binding, which curbs the ability of Scribble to promote Hippo pathway activity. The consequences are stabilization and nuclear accumulation of TAZ, growth and survival of tumor cells and elevated breast cancer development.
The role of the focal adhesion protein KANK1 in cancer progression is not yet clearly understood. Here the authors find that KANK1 competes with the polarity protein Scribble at cell-cell junctions for NOS1AP binding, leading to TAZ stabilization and activation, and breast cancer progression.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Max Planck Institute of Biochemistry, Department of Molecular Medicine, Martinsried, Germany (GRID:grid.418615.f) (ISNI:0000 0004 0491 845X)
2 The University of Hong Kong, School of Biomedical Sciences, LKS Faculty of Medicine, Hong Kong SAR, China (GRID:grid.194645.b) (ISNI:0000 0001 2174 2757)
3 Dalhousie University, Departments of Pharmacology and Surgery, Halifax, Canada (GRID:grid.55602.34) (ISNI:0000 0004 1936 8200)
4 University Cologne, Institute of Pathology, Medical Faculty, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777)
5 The University of Hong Kong, School of Biomedical Sciences, LKS Faculty of Medicine, Hong Kong SAR, China (GRID:grid.194645.b) (ISNI:0000 0001 2174 2757); The Chinese University of Hong Kong, School of Biomedical Sciences, Faculty of Medicine, Hong Kong SAR, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482)